Welcome to our dedicated page for Vir Biotechnology SEC filings (Ticker: VIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vir Biotechnology, Inc. (Nasdaq: VIR) files reports and disclosures with the U.S. Securities and Exchange Commission that provide detailed information on its clinical programs, collaborations and financial position. This SEC filings page aggregates those documents and pairs them with AI-generated summaries to help readers understand the key points in each filing.
For Vir Biotechnology, important filings include Form 8-K current reports describing material events, such as the license agreement with Norgine Pharma UK Limited for commercial rights to the tobevibart and elebsiran combination in chronic hepatitis delta across Europe, Australia and New Zealand, and updates on clinical data from the SOLSTICE Phase 2 trial. Other 8-K filings reference quarterly financial results, including cash, cash equivalents and investments, research and development spending, and progress across the ECLIPSE registrational program and oncology pipeline.
Investors following Vir Biotechnology’s infectious disease and oncology strategy can use this page to locate quarterly and annual financial disclosures, business updates reported via 8-K, and other SEC documents that discuss collaborations, licensing arrangements and clinical milestones. AI-powered tools highlight key terms, summarize complex sections and make it easier to identify information related to chronic hepatitis delta development, PRO-XTEN dual-masked T-cell engagers, and the company’s use of platforms such as dAIsY and PRO-XTEN.
The page also provides access to filings that may include details on revenue categories such as collaboration, contract, grant and license revenue, as well as information about material agreements and clinical trial updates referenced in attached press releases. Real-time integration with EDGAR means new Vir Biotechnology filings appear here as they are made public, with concise AI explanations to support faster review and comparison over time.
Vir Biotechnology (VIR) reported a Form 4 for insider activity. Vanina de Verneuil, EVP and General Counsel, executed an automatic sale of 1,365 shares of common stock at $5.863 on 11/03/2025 to satisfy tax withholding obligations upon RSU vesting.
After the transaction, she directly beneficially owns 80,595 shares. This total includes 2,500 shares acquired on May 30, 2025 through the employee stock purchase program.
Vir Biotechnology (VIR) director reported an open‑market sale of company stock. On 11/03/2025, the reporting person sold 22,000 shares of common stock at a weighted average price of $5.6385, coded “S”. The sale was made pursuant to a Rule 10b5‑1 trading plan adopted on 03/27/2025.
Following the transactions, the reporting person beneficially owned 1,210,391 shares, held directly. The shares were sold in multiple trades with prices ranging from $5.51 to $5.90.
Vir Biotechnology (VIR): Form 4 insider transactions disclosed. SVF Endurance (Cayman) Limited, affiliated with SoftBank Vision Fund (AIV M1) L.P. and managed by SB Investment Advisers (UK) Limited, reported open-market sales executed under a Rule 10b5-1 plan entered on September 3, 2025. On October 28, 2025, it sold 24,453 shares at a weighted average price of $6.5025, and on October 29, 2025, it sold 100 shares at $6.49. Following these trades, indirect beneficial ownership stood at 14,573,983 shares. The reporting relationship indicates Director status, and the filing is made by more than one reporting person.
Vir Biotechnology (VIR): insider share sales disclosed. SVF Endurance (Cayman) Limited, affiliated with SoftBank Vision Fund, reported open‑market sales of VIR common stock pursuant to a Rule 10b5‑1 plan entered on September 3, 2025.
On October 24, 2025, 46,696 shares were sold at a weighted average price of $5.9595, with trades ranging from $5.92 to $6.0212. On October 27, 2025, 66,403 shares were sold at a weighted average price of $6.0477, with trades ranging from $5.93 to $6.18. Following these transactions, 14,598,536 shares were beneficially owned on an indirect basis through SVF Endurance, as noted in the filing’s footnotes regarding SoftBank Vision Fund’s management structure.
Vir Biotechnology (VIR): insider transaction SVF Endurance (Cayman) Limited, affiliated with SoftBank Vision Fund, reported open‑market sales made pursuant to a Rule 10b5‑1 trading plan entered into on September 3, 2025.
It sold 144,266 shares on October 22, 2025 at a weighted average price of $6.1529, and 154,383 shares on October 23, 2025 at a weighted average price of $5.9898. After these transactions, the reporting person disclosed beneficial ownership of 14,711,635 shares, held indirectly.
Vir Biotechnology (VIR) insider filing shows affiliated entities of SoftBank reported open‑market sales of common stock. SVF Endurance (Cayman) Limited sold 220,535 shares on 10/20/2025 at a weighted average price of $6.1998 and sold 109,675 shares on 10/21/2025 at a weighted average price of $6.3002. The transactions were effected pursuant to a Rule 10b5‑1 trading plan entered on September 3, 2025.
Following these sales, the reporting persons showed indirect beneficial ownership of 15,119,959 shares after the 10/20/2025 trades and 15,010,284 shares after the 10/21/2025 trades, held through SVF Endurance (Cayman) Limited as described in the footnotes.
Vir Biotechnology (VIR): Form 4 insider transaction — SVF Endurance (Cayman) Limited, an affiliate of SoftBank Vision Fund, reported open‑market sales executed under a Rule 10b5-1 trading plan. On 10/15/2025, it sold 16,671 shares of common stock at a weighted average price of $6.0702. On 10/16/2025, it sold 12,844 shares at a weighted average price of $6.1014. Following these transactions, indirect beneficial ownership is reported as 15,340,494 shares. The filing notes the weighted‑average price ranges for each date and offers to provide full trade‑by‑trade detail upon request.
Vir Biotechnology (VIR): A reporting group affiliated with SoftBank—SVF Endurance (Cayman) Limited—reported open‑market sales of Vir common stock under a Rule 10b5‑1 trading plan entered into on September 3, 2025. On 10/09/2025, it sold 249,060 shares at a weighted average price of $6.1428. On 10/10/2025, it sold 2,300 shares at a weighted average price of $6.0752.
Following these transactions, the filing shows beneficial ownership of 15,372,309 shares after the first sale and 15,370,009 shares after the second, held indirectly, with SVF Endurance as record holder and SB Investment Advisers (UK) Limited managing SoftBank Vision Fund (AIV M1) L.P. The reporting person is listed as a Director and 10% Owner.
SVF Endurance (Cayman) Ltd and related SoftBank entities reported insider sales of Vir Biotechnology, Inc. (VIR) common stock under a Rule 10b5-1 plan. The filings show a sale of 72,133 shares on 10/07/2025 at a weighted average price of
SVF Endurance (Cayman) Ltd and affiliated reporting persons disclosed insider sales of 524,297 shares of Vir Biotechnology, Inc. (VIR) across two dates in early October 2025. The sales occurred on
The filing clarifies that SVF Endurance (Cayman) Limited is the record holder and is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P., with SB Investment Advisers (UK) Limited appointed as the alternative investment fund manager responsible for investment decisions.
FAQ
What is the current stock price of Vir Biotechnology (VIR)?
What is the market cap of Vir Biotechnology (VIR)?
